What if a weight-loss shot helped your heart, kidneys and liver before the scale moved? A Fox News Health explainer published Oct. 15 lays out a growing list of health problems these GLP-1 drugs may help with. The weight-loss benefits of GLP-1 drugs may be only the start.
The headline promise is bold: benefits that show up “before the pounds even come off.” The research behind it is a mixed picture. Some of it is strong, and some of it is early. Here is how it sorts out.
Heart health: the strongest GLP-1 health benefits
The heart is where the evidence is deepest. Fox reports that a study in The Lancet found semaglutide cut heart attacks, strokes and cardiovascular death. The patients had existing heart disease and were overweight or obese. The benefit showed up across body weights, and weight loss did not fully explain it.
Independent research backs the general direction. A recent meta-analysis of 16 trials covered 23,467 non-diabetic participants. It found these drugs cut major adverse cardiovascular events by 20 percent. Wegovy is also already FDA-approved to lower heart attack and stroke risk in adults, according to Today.
Semaglutide benefits for kidneys, liver and knees
The list continues from there. Fox cites the FLOW trial. It found semaglutide lowered the risk of major kidney complications and cardiovascular death by 24 percent. Those patients had type 2 diabetes and chronic kidney disease.
On the liver, Fox says 62.9 percent of semaglutide patients saw their MASH resolve without worsening scarring. Only 34.3 percent on placebo did. MASH is a fatty liver disease that can lead to serious damage.
Then there are the joints. The STEP 9 trial found semaglutide reduced knee osteoarthritis pain and improved physical function in adults with obesity. Fox is careful to add that the drugs’ ability to actually repair damaged cartilage has not been established. Less pain is not the same as a rebuilt knee.
Lungs, the mind and other weight-loss shot benefits
Fox also points to real-world research presented at the European Respiratory Society Congress. It linked GLP-1 use to fewer asthma attacks and COPD flare-ups. That evidence comes from real-world data, not randomized trials. Treat it as a promising lead rather than a verdict.
The Fox list also touches on mental health and addiction. The research there is still early, and we could not confirm every detail of that section. Safety questions also keep surfacing, including a suspected vision-loss case reported in South Korea.
The catch: benefits beyond weight loss, or just the pounds?
So who gets the credit, the medicine or the pounds lost? Nobody knows for sure. A 2025 Cell Reports Medicine review says scientists still only partly understand how these drugs deliver benefits apart from weight loss. CNN reported in April that liver, heart and kidney benefits appear to be at least partly independent of weight loss. Calming inflammation may be a key reason.
Notice the careful wording. The Fox piece calls these “potential” benefits, and its own sections admit more studies are needed. The headline is stronger than the fine print, so it helps to read past it.
Here’s the thing for patients
If you take one of these drugs, or you’re thinking about it, the takeaway is not “skip your doctor.” These are prescription medicines with real side effects and real costs. The weight-loss benefits of GLP-1 drugs keep growing on paper. That makes it worth a real conversation with your physician about your own heart, kidney and liver risk.
The pipeline is moving fast, too. Lilly’s next-generation contender retatrutide posted big diabetes weight-loss results in a phase 3 trial.
One caution on the numbers. We pulled the trial figures from Fox’s reporting and could not check each one against the original journal papers. Fox’s Lancet attribution for the heart finding is also unconfirmed, so treat the specifics as reported claims.
The next question is the big one. If more trials show these benefits don’t depend on weight loss, will we still call these weight-loss shots at all?
